Moore RD - Search Results

1

Aging and loss to follow-up among youth living with human immunodeficiency virus in the HIV Research Network.

Agwu AL, Lee L, Fleishman JA, Voss C, Yehia BR, Althoff KN, Rutstein R, Mathews WC, Nijhawan A, Moore RD, Gaur AH, Gebo KA. Agwu AL, et al. Among authors: moore rd. J Adolesc Health. 2015 Mar;56(3):345-51. doi: 10.1016/j.jadohealth.2014.11.009. J Adolesc Health. 2015. PMID: 25703322 Free PMC article.

2

A comprehensive plan for managed care of patients infected with human immunodeficiency virus.

Bartlett JG, Moore R. Bartlett JG, et al. Clin Infect Dis. 1999 Jul;29(1):50-5. doi: 10.1086/520179. Clin Infect Dis. 1999. PMID: 10433564

3

Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort.

Perez JL, Moore RD. Perez JL, et al. Among authors: moore rd. Clin Infect Dis. 2003 Jan 15;36(2):212-8. doi: 10.1086/345669. Epub 2003 Jan 6. Clin Infect Dis. 2003. PMID: 12522755

4

Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy.

Gebo KA, Keruly J, Moore RD. Gebo KA, et al. Among authors: moore rd. J Gen Intern Med. 2003 Feb;18(2):104-11. doi: 10.1046/j.1525-1497.2003.10801.x. J Gen Intern Med. 2003. PMID: 12542584 Free PMC article.

5

Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.

Sterling TR, Chaisson RE, Moore RD. Sterling TR, et al. Among authors: moore rd. Clin Infect Dis. 2003 Mar 15;36(6):812-5. doi: 10.1086/367934. Epub 2003 Feb 27. Clin Infect Dis. 2003. PMID: 12627368

6

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Sethi AK, et al. Among authors: moore rd. Clin Infect Dis. 2003 Oct 15;37(8):1112-8. doi: 10.1086/378301. Epub 2003 Sep 19. Clin Infect Dis. 2003. PMID: 14523777

7

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73. doi: 10.1097/00126334-200310010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 14526205

8

The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV.

Gebo KA, Moore RD, Fleishman JA. Gebo KA, et al. Among authors: moore rd. Hopkins HIV Rep. 2003 Nov;15(6):5-6. Hopkins HIV Rep. 2003. PMID: 14974424 No abstract available.

9

Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study.

Lucas GM, Weidle PJ, Hader S, Moore RD. Lucas GM, et al. Among authors: moore rd. Clin Infect Dis. 2004 Jun 1;38 Suppl 5:S409-13. doi: 10.1086/421405. Clin Infect Dis. 2004. PMID: 15156431 Clinical Trial.

10

Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Gebo KA, Gallant JE, Keruly JC, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1028-33. doi: 10.1097/00126334-200408150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15247555

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

925 results

Search Page

Filters